Showing 1 - 20 results of 49 for search '"N,N-dimethyltryptamine"', query time: 0.12s Refine Results
  1. 1

    Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations by Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton

    Published 2022-12-01
    “…Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is believed to have potential as a therapeutic option in several psychiatric disorders. …”
    Get full text
    Article
  2. 2

    N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner—A pharmacokinetic/pharmacodynamic analysis by Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton

    Published 2023-04-01
    “…Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques. …”
    Get full text
    Article
  3. 3

    Optimized infusion rates for N,N‐dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework by Emma Eckernäs, Jeroen Koomen, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton

    Published 2023-10-01
    “…Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. …”
    Get full text
    Article
  4. 4

    Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine by Dario A. Dornbierer, Dario A. Dornbierer, Dario A. Dornbierer, Laurenz Marten, Laurenz Marten, Jovin Mueller, Helena D. Aicher, Helena D. Aicher, Helena D. Aicher, Michael J. Mueller, Michael J. Mueller, Michael J. Mueller, Martina Boxler, Michael Kometer, Davor Kosanic, Robin von Rotz, Maxim Puchkov, Thomas Kraemer, Hans-Peter Landolt, Hans-Peter Landolt, Erich Seifritz, Erich Seifritz, Milan Scheidegger, Milan Scheidegger

    Published 2023-11-01
    “…Recently, the Amazonian plant medicine “ayahuasca”—containing the psychedelic compound N,N-dimethyltryptamine (DMT) and numerous β-carboline alkaloids, such as harmine—has been suggested to exhibit beneficial effects in patients with affective and other mental health disorders. …”
    Get full text
    Article
  5. 5
  6. 6
  7. 7
  8. 8

    A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers by J. Reckweg, N. Mason, C. Van Leeuwen, S. Tönnes, T. Terwey, J. Ramaekers

    Published 2022-06-01
    “… Introduction 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. …”
    Get full text
    Article
  9. 9
  10. 10
  11. 11
  12. 12

    Effects of hallucinogenic drugs on the human heart by Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs

    Published 2024-02-01
    “…Here, we will review the inotropic and chronotropic actions of bufotenin, psilocin, psilocybin, lysergic acid diethylamide (LSD), ergotamine, ergometrine, N,N-dimethyltryptamine, and 5-methoxy-N,N-dimethyltryptamine in the human heart.…”
    Get full text
    Article
  13. 13

    Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities by Attila eSzabo

    Published 2015-07-01
    “…In this paper, the immunomodulatory potential of classical serotonergic psychedelics, including N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-iodoamphetamine (DOI) and 3,4-methylenedioxy-methamphetamine (MDMA) will be discussed from a perspective of molecular immunology and pharmacology. …”
    Get full text
    Article
  14. 14

    Psychedelics: A new era of treatment? by S. Torres

    Published 2021-04-01
    “… Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. …”
    Get full text
    Article
  15. 15

    A Review of Aeruginascin and Potential Entourage Effect in Hallucinogenic Mushrooms by P. Chue, A. Andreiev, E. Bucuci, C. Els, J. Chue

    Published 2022-06-01
    “… Introduction The 5-HT2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. …”
    Get full text
    Article
  16. 16

    Association between lifetime classic psychedelic use and hypertension in the past year by Simonsson, O, Hendricks, PS, Carhart-Harris, R, Kettner, H, Osika, W

    Published 2021
    “…Notably, when analyzing the associations between hypertension in the past year and lifetime use of the main classes of classic psychedelics, namely tryptamines (N,N-dimethyltryptamine, ayahuasca, and psilocybin), lysergic acid diethylamide (a lysergamide), and phenethylamines (mescaline, peyote, and San Pedro), only the association with lifetime tryptamine use was significant (adjusted odds ratio, 0.80 [0.73–0.89]; P=0.0001). …”
    Journal article
  17. 17

    Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders by Nataliya Vorobyeva, Alena A. Kozlova

    Published 2022-06-01
    “…In this review, we will discuss the three classic serotonergic naturally occurring psychedelics, psilocybin, ibogaine, and N, N-dimethyltryptamine, focusing on their pharmacological properties and clinical potential. …”
    Get full text
    Article
  18. 18

    β-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses by Cowen, P, Grahame-Smith, D, Green, A, Heal, D

    Published 1982
    “…Clenbuterol (5 mg/kg) also enhanced the hyperactivity syndrome produced by the 5-HT agonist, 5-methoxy N,N-dimethyltryptamine (2 mg/kg) and the combination of tranylcypromine (10 mg/kg) and L-tryptophan (50 mg/kg). …”
    Journal article
  19. 19

    beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses. by Cowen, P, Grahame-Smith, D, Green, A, Heal, D

    Published 1982
    “…Clenbuterol (5 mg/kg) also enhanced the hyperactivity syndrome produced by the 5-HT agonist, 5-methoxy N,N-dimethyltryptamine (2 mg/kg) and the combination of tranylcypromine (10 mg/kg) and L-tryptophan (50 mg/kg). …”
    Journal article
  20. 20

    A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience by Andrew Robert Gallimore, Rick Strassman

    Published 2016-07-01
    “…The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance. …”
    Get full text
    Article